We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
South Africa's National Treasury is proposing tax breaks of around
ZAR2.8bn (US$427.61mn) to ZAR3.8bn (US$580.34mn), to encourage greater medical scheme coverage among low-to-middle income earners.
Government sources in Peru have insisted that a Free Trade Agreement (FTA) with the US, set to be signed on Nov. 20, will not lead to higher drug prices.
A new report submitted to the European Parliament has claimed that although the UK is one of the leading countries in the European Union (EU) in terms of cancer research funding, it falls behind other EU countries in terms of patient access to new cancer treatments.
Thailand has expanded its universal health care scheme to provide immediate access to anti-retroviral (ARV) treatments for around 80,000 people with HIV/AIDS.
Jubilant Organosys Ltd. (Jubilant), an integrated pharmaceuticals company, has
acquired Target Research Associates, Inc. (Target), a US-based, full service
Clinical Research Organization (CRO).
Epix Pharmaceuticals Inc. (EPIX.O: Quote, Profile, Research) on Wednesday said
it won European regulatory approval for its blood pool contrast agent Vasovist.
Sankyo and Santen Pharmaceutical have signed a licensing agreement on CS-011
(rivoglitazone), Sankyo's proprietary agent designed for the treatment of diabetes.
Newron Pharmaceuticals SpA, a late-stage discovery and development company focusing
on novel CNS therapies, today announced the completion of a EUR30 million Series
B round with the addition of TVM in a second closing of EUR7 million.
Gentium S.p.A. (AMEX:GNT) (the "Company") announced today that it
has entered into definitive agreements for a $10.9 million private placement
of 1.551,125 million of its American Depository Shares (ADSs) at a price of
$7.05 per ADS.